Feds could soon bring COVID-style fight to superbug threat

COVID-19 has inspired renewed urgency in the need for weapons to combat antimicrobial resistant infections and new hope of government funding to meet the challenge.

By Karissa Waddick • Sept. 13, 2022

From the ‘go-go days’ to a bubble crunch — the biotech sector faces its next challenge

The highs of the sector in early 2021 gave way to a bear market that persisted into the second half of this year — but there's hope the bubble hasn't popped for good.

By Michael Gibney • Sept. 12, 2022

Explore the Trendline➔

Oncology

As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

By PharmaVoice staff

Woman of the Week: Foresite Capital’s Cindy Mesaros

The longtime marketing pro details her fascinating career journey and how she’s positioning early stage health companies to thrive. 

By Taren Grom • Sept. 7, 2022

First 90 Days: Adaptive Biotech’s Tycho Peterson

A long-time analyst, Tycho Peterson brings his business savvy to the C-suite at Adaptive, where he began as CFO in June with a knowledge of what works and what doesn't in the diagnostics space.

By Michael Gibney • Sept. 1, 2022

Pharma’s renewed sickle cell investment lifts a once-shirked disease

Pfizer's $5.4 billion deal to acquire Global Blood Therapeutics invigorated the fast-growing market, and patients are fit to be the benefactors.

By Kelly Bilodeau • Sept. 1, 2022

Moderna’s lawsuit against Pfizer and BioNTech explained in 10 quotes

The biotech says that its competitors’ COVID-19 vaccine copied proprietary mRNA technology. Here’s a breakdown of the case.

By Karissa Waddick • Aug. 31, 2022

Leading the industry’s next potential game-changer in drug discovery

Rachel Meyers, chief scientific officer at Faze Medicines, is helping guide the company towards the development of biomolecular condensates — an emerging field that could transform drug discovery.

By Alexandra Pecci • Aug. 29, 2022

Moderna, Eli Lilly and Schrödinger seek to boost financial and people strategies with key new hires

How the latest personnel shifts are impacting each company and the industry at large. 

By Karissa Waddick • Aug. 24, 2022

Patents, pandemics and pricing: a peek at the top drug from every big pharma

A look at how the biggest pharma companies in the world and their top-selling drugs fared in the first half of the year.

By Michael Gibney • Aug. 22, 2022

3 ways pharma can prep for Biden’s sweeping drug pricing policies

Now that Medicare will be able to negotiate drug prices under the Inflation Reduction Act, the industry can expect to see some changes. Here are some tips on how to navigate the changing tide.

By Karissa Waddick • Aug. 18, 2022

Inventing the COVID vax pill: a matter of convenience and durability

Recent data from Vaxart’s phase 1 trial of its COVID-19 inoculation pill shows potential.

By Kelly Bilodeau • Aug. 17, 2022

Right under our noses: Could COVID-19 vaccines be better as nasal spray?

Nasal vaccines under development by Codagenix, Xanadu Bio and others have the potential to finally help reduce virus transmission and breakthrough infections.

By Kelly Bilodeau • Aug. 16, 2022

As pharma M&A ramps up, U.S. execs are bullish on more deals

What top executives at Merck, Pfizer and more are saying about M&A as they move into the second half of the year.

By Michael Gibney • Aug. 11, 2022

4 ways to nail the launch of your cell therapy

A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.

By Meagan Parrish • Aug. 10, 2022

How real world evidence is impacting rare disease drug development

ICON’s Will Maier shares how a more patient-focused approach to trials is leading to alternatives for randomization.

By Kim Ribbink • Aug. 9, 2022

Turning harp seal contraceptives into a ‘new genre’ of cancer treatments

With Andrew Hall at its helm, IMV has evolved an animal contraceptive into a unique drug delivery platform aimed at creating targeted cancer immunotherapies for humans.

By Alexandra Pecci • Aug. 9, 2022

Are Big Pharma CEOs earning their pay?

While compensation packages at the top may not always reflect value, it’s not necessarily an industrywide problem.

By Kelly Bilodeau • Aug. 8, 2022

Editas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires

How these latest executive personnel changes are impacting the industry. 

By Karissa Waddick • Aug. 3, 2022

Woman of the Week: Alloy Therapeutics’ Heather Schwoebel

The CBO and COO is leaning on her experience navigating the unknown to turn Alloy into an innovation multiplier.

By Taren Grom • Aug. 3, 2022

Taking probiotics where they’ve never gone before

How Seed Health is transforming the microbiome therapeutic market with its pharma-focused drug development approach.

By Karissa Waddick • Aug. 2, 2022

How a speech analysis tool could transform diagnosis and research for Alzheimer’s and beyond

WinterLight’s machine learning platform assesses speech to more accurately identify neurodegenerative diseases.

By Kim Ribbink • Aug. 1, 2022

A glimpse inside Bristol Myers Squibb’s integration with Celgene

Catherine Owen, senior vice president of major markets, discusses the hurdles — and successes — of bringing the two ‘powerhouses’ together.

By Meagan Parrish • Aug. 1, 2022

What’s next for Biogen? Here’s what executives are saying

A trickling launch for Aduhelm and a middling earnings report give Biogen executives a lot to talk about. Is there hope?

By Michael Gibney • July 27, 2022

Democrats think they've found a balance between drug innovation and pricing negotiation

A look at Congress’ push to pass drug pricing reform and why the latest attempt could actually succeed.

By Karissa Waddick • July 26, 2022

The earlier the better: New consortium leverages infant screening to accelerate treatment

Inozyme Pharma has joined a genomic sequencing program developing a novel rapid test for 388 genetic diseases.

By Kim Ribbink • July 25, 2022